Bipolar disorder is a complex, recurrent, and severe mental illness that has an onset typically between 13 and 30 years of age and a lifetime prevalence of 1.4%. 1 It is characterised by episodes of mania or hypomania with elation, overactivity, and disinhibited behaviour, as well as episodes of depression with profound loss of interest and motivation, often with milder depressed mood in between episodes. Bipolar disorder is associated with an increased risk of suicide and physical illness, such as ischaemic heart disease, diabetes, chronic obstructive airways disease, pneumonia, and unintentional injury. 2 Around two thirds of people with bipolar disorder also experience another mental disorder, usually anxiety disorders, substance misuse disorders, or impulse control disorders. 1 The risk of recurrence in the year after a mood episode is especially high (50% in one year and >70% at four years) compared with other psychiatric disorders, 3 and this has important implications for the long term management of the disorder.
This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE) on assessing and managing bipolar disorder in adults, children, and young people. 4 
Recommendations
NICE recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Care for adults, children, and young people across all phases of bipolar disorder
• Use this guideline in conjunction with the NICE clinical guidance on service user experience in adult mental health 5 to improve the experience of care by: -Promoting a positive recovery message from the point of diagnosis and throughout care 
Managing bipolar depression in adults in secondary care
• Offer adults with bipolar depression:
-A psychological intervention that has been developed specifically for bipolar disorder and has a published evidence based manual describing how it should be delivered or -A high intensity psychological intervention (cognitive behavioural therapy, interpersonal therapy, or behavioural couples therapy) in line with the NICE clinical guideline on depression. 
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• If a person develops moderate or severe bipolar depression and is not taking a drug to treat the disorder, offer fluoxetine combined with olanzapine, or quetiapine on its own, depending on the person's preference and previous response to treatment.
• If the person prefers, consider either olanzapine (without fluoxetine) or lamotrigine on its own.
• Consider the use of lamotrigine if there is no response to fluoxetine combined with olanzapine or to quetiapine on its own.
(New recommendation.) [Based on a systematic review, network meta-analysis, and economic model]
• If a person develops moderate or severe bipolar depression and is already taking lithium, check the person's plasma lithium level. If it is inadequate, increase the dose of lithium; if it is at maximum level, add either fluoxetine combined with olanzapine or quetiapine on its own, depending on the person's preference and previous response to treatment.
• If the person prefers, consider adding olanzapine (without fluoxetine) or lamotrigine to lithium.
• If there is no response to the addition of fluoxetine combined with olanzapine or quetiapine on its own, stop the additional treatment and consider adding lamotrigine to lithium. Managing bipolar disorder in children and young people
• To treat mania or hypomania in young people see NICE's technology appraisal guidance on aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder, 12 and also consider the recommendations for adults. In children, refer to the BNF for Children to modify drug treatments, 13 be aware of the increased potential for a range of side effects, and do not routinely 
Overcoming barriers
There is a perception that because bipolar disorder has important genetic and biological influences it must be treated with drugs, and the drug of choice for bipolar depression for many professionals is an antidepressant. 14 This misconception is challenged by this guideline, which finds that psychological treatments are effective in the treatment of bipolar depression in primary and secondary care and in preventing recurrence. Psychological treatments are also important for young people, both because young people may benefit from them and because they are at greater risk of harm with drug treatment. 15 However access to psychological therapies is currently insufficient for adults and young people with bipolar disorder. For adults, this guideline also finds that some antipsychotics are effective in the treatment of bipolar depression, but lithium (rather than antipsychotics) should be the first line drug to prevent relapse. A major driver for these changes will be the establishment of quality networks and national audit. In adults, many mental health workers have taken the view that smoking, not taking exercise, and having a poor diet are unimportant compared with the enormous impact of a bipolar illness. 16 These beliefs have contributed to people with bipolar disorder dying from preventable diseases much earlier than others. 2 This guideline emphasises the importance of maintaining good physical health for people with severe mental health problems, such as bipolar disorder, and we hope it will contribute to a change in professional attitudes and practice.
There has been much controversy over the diagnosis and treatment of children and young people with possible bipolar disorder. In the United States, children as young as 4 or 5 years are being treated with drugs, 17 using criteria for diagnosis that would not be accepted in the NHS. Thus, increasing numbers of children and young people are taking antipsychotics, 18 which are associated with serious adverse events, including increased prolactin levels, rapid weight gain, and increased risk of diabetes. 12 The previous NICE guideline rejected the extension of bipolar disorder into childhood and suggested that clinicians apply stricter criteria to adolescents, 19 but the diagnosis and treatment of children and adolescents has continued, mostly in the US. 18 This is despite evidence that symptoms are not stable over time 20 and despite limited evidence that young people benefit from the treatments commonly used in adults. Importantly, trials in the US show that many children under 13 years diagnosed as having bipolar disorder also have attention-deficit/hyperactivity disorder, 17 21 which might be a more appropriate diagnosis. The updated guideline reinforces the findings of the last guideline and finds that extensive use of this diagnosis in children could cause more harm than good. 
Further information on the guidance
An important prompt for this guideline update was a high quality network meta-analysis of treatments for acute mania published in 2011, in which haloperidol, olanzapine, quetiapine, and risperidone emerged as the most effective treatments. 8 The previous guideline recommended a range of other alternatives alongside antipsychotics, including valproate and lithium, interventions which were ranked much lower in the network.
Methods
This guideline, which is an update of NICE clinical guideline 38, 19 was developed by the National Collaborating Centre for Mental Health using NICE guideline methods (www.nice.org.uk/guidelinesmanual). The guideline review process involved comprehensive and systematic literature searches to identify relevant evidence for the clinical and economic reviews, with critical appraisal of the quality of the identified evidence. Results of intervention studies were compared using pair-wise and network meta-analyses. Results of the network meta-analysis were used to inform an economic model. A multidisciplinary team of healthcare professionals from psychiatry, psychology, pharmacology, occupational therapy, general practice, and nursing, as well as service user and carer representatives (forming the GDG) was established to review the evidence and develop the subsequent recommendations. The guideline then went through an external consultation with stakeholders. The GDG considered the stakeholders' comments, reanalysed the data where necessary, and modified the guideline as appropriate.
NICE has produced three different versions of the guideline: a full version; a summary version known as the "NICE guideline;" and a version for children, young people, and adults with bipolar disorder, their parents and carers, and the public. 11 All these versions, as well as a pathway, are available from the NICE website. Further updates of the guideline will be produced as part of NICE's guideline development programme.
Future research
• What is the clinical and cost effectiveness of structured psychological interventions for young people with bipolar depression?
• In the maintenance treatment of bipolar disorder, what are the relative effects on quality of life of lithium, an antipsychotic (haloperidol, olanzapine, quetiapine or risperidone), or a combination of lithium and an antipsychotic?
• What is the clinical and cost effectiveness of fluoxetine combined with olanzapine versus an alternative selective serotonin reuptake inhibitor combined with olanzapine in the treatment of moderate to severe bipolar depression?
• What is the clinical and cost effectiveness of a specialised collaborative care service for people admitted to hospital with bipolar disorder compared with usual treatment delivered by generic care services?
• What is the clinical and cost effectiveness of face to face cognitive behavioural therapy compared with internet facilitated cognitive behavioural therapy in the long term management of bipolar disorder?
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